Women's Cancer News
Jul. 23, 2014

HPV test vs. Pap for gauging cervical cancer risk
HealthDay News via WebMD
A new study involving data on more than 1 million women finds the HPV test outperforming the standard Pap test in assessing cervical cancer risk. Researchers at the U.S. National Cancer Institute (NCI) conclude that a negative test for HPV (human papillomavirus) infection is associated with an extremely low risk for cervical cancer and provides greater assurance of low cervical cancer risk than a negative Pap test.More

Study finds new cancer risk from hysterectomy device
The Wall Street Journal (Subscription Required)
New research published by a prestigious medical journal estimates that nearly 1 in 370 women undergoing a hysterectomy with a common women's surgical device have a hidden uterine cancer, the largest assessment yet of the risk posed by a tool that is under scrutiny for its potential to spread undetected cancer. The study, published by Columbia University doctors in the Journal of the American Medical Association, sheds new light on the potential hazards of a surgical tool called a power morcellator that is used to remove uterine growths, fibroids, in laparoscopic surgery. It also found that the device might spread a wider range of cancers than previously believed.More

HPV persists significantly longer in African-American women
Healio
The time it took for black women to clear a high-risk HPV infection was nearly double that of white women, according to a study published in the Journal of Infectious Diseases. Researchers conducted a prospective longitudinal study by recruiting women at a college student health center. The study included 113 black women and 326 white women who visited the clinic twice a year for HPV testing and Pap smears. Within the cohort, there were 2,121 study visits and 906 (42.7 percent) were positive for HPV. White women were HPV positive on 40 percent of the visits, but black women were positive on 51 percent of the visits.More

The importance of reducing patients' symptom burden in cancer
Medscape (Free Login Required)
Dr. Maurie Markman discusses a paper that recently appeared in the International Journal of Gynecological Cancer, "Symptom Burden and Outcomes of Patients With Platinum Resistant/Refractory Recurrent Ovarian Cancer: A Reality Check: Results of Stage 1 of the Gynecologic Cancer Intergroup Symptom Benefit Study."More

Self-assembling nanoparticle could improve MRI scanning for cancer diagnosis
(e) Science News
Scientists have designed a new self-assembling nanoparticle that targets tumors, to help doctors diagnose cancer earlier. The new nanoparticle, developed by researchers at Imperial College London, boosts the effectiveness of magnetic resonance imaging (MRI) scanning by specifically seeking out receptors that are found in cancerous cells. The nanoparticle is coated with a special protein, which looks for specific signals given off by tumors, and when it finds a tumor it begins to interact with the cancerous cells. This interaction strips off the protein coating, causing the nanoparticle to self-assemble into a much larger particle so that it is more visible on the scan.More

Breast cancer drug has a surprising new application, study finds
TIME
An early study published in Clinical Cancer Research shows that gel-based tamoxifen may be as effective as the oral drug, and have fewer side effects. Dr. Seema Khan, professor of surgery at Northwestern University Feinberg School of Medicine, reports that putting the drug in a gel, and applying it directly to the breast tissue, where it needs to work, may have merit.More

Structure of protein vital to cancer development is mapped
Medical News Today
A major breakthrough has been made by scientists who have successfully managed to map out the structure of a complicated protein that is regarded to be one of the most important in cell division. This knowledge could be used in the future in the development of cancer drugs.More